Acticor Biotech is a spin-off from INSERM (the French National Institute of Health and Medical Research).

The Paris-based company is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment directed against a novel target of major interest, platelet glycoprotein VI. Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the brain.

In May 2022, Acticor presented positive results from its Phase Ib/IIa study, ACTIMIS, confirming the safety profile and showing a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group in patients with stroke.